[Translation] An adaptive, randomized trial evaluating the efficacy, safety, and tolerability of LNP023 in combination with standard therapy (with or without oral corticosteroid therapy) in adult patients with active lupus nephritis type III-IV (+/-V) , double-blind, dose-finding, parallel-group, placebo-controlled, multicenter, phase II trial
本研究分为两部分,总体目的是在活动性狼疮肾炎(ISN/RPS III或IV型,伴有或没有V型特征)患者中评估在MMF/MPS免疫抑制治疗(联合或替代皮质激素逐渐减量方案)的基础上加用LNP023的疗效、安全性和耐受性。
[Translation] The overall aim of this two-part study was to evaluate the efficacy of MMF/MPS immunosuppressive therapy (combined with or instead of tapering corticosteroids) in patients with active lupus nephritis (ISN/RPS type III or IV, with or without type V features). The curative effect, safety and tolerability of adding LNP023 on the basis of dosage regimen).